Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Initial Treatment Vs Watch and Wait in Advanced-Stage Follicular Lymphoma in the Rituximab Era - an Analysis of the National Cancer Database (NCDB)

Ning Dong, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Franco Castillo Tokumori, MD, Bijal Shah, MD, Sameh Gaballa, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Julio C. Chavez, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-138749

Published: 2020

Journal Articles

Chemotherapy Based Salvage Regimens Are Associated with Poor Outcomes in Refractory Classical Hodgkin Lymphoma

Ashley Rose, MD, Dakota Jenneman, MD, Leidy Isenalumhe, MD, Julio C. Chavez, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Celeste Bello, MD, Hayder Saeed, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-138815

Published: 2020

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Blood (2019) 134 (Supplement_1): 474.

https://doi.org/10.1182/blood-2019-127235

Published: 2019

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Nikesh Shah, MD, Franco Castillo-Tokumori, MD, Julio C. Chavez, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 3991.

https://doi.org/10.1182/blood-2019-127291

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5483.

https://doi.org/10.1182/blood-2019-132211

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Anthony M. Hunter, MD, Nelson Ryan, PharmD, Mohammad Hussaini, MD, Ratilal Akabari, Alan F. List, MD, Jeffrey Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Javier Pinilla Ibarz, MD PhD, Andrew T Kuykendall, MD, Ling Zhang, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4167.

https://doi.org/10.1182/blood-2019-130196

Published: 2019

Journal Articles

Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis

Kristen Gonter-Aubin, DO, Daniel Alan Kerr, MD PhD, Ashley Rose, MD, Thanh Lana Nguyen, MDBS, Julio C. Chavez, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 1542.

https://doi.org/10.1182/blood-2019-129028

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 3382.

https://doi.org/10.1182/blood-2019-131207

Published: 2019

Journal Articles

Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Seongseok Yun, MD PhD, Jose Sandoval-Sus, MD, Todd C Knepper, PharmD, Jamie Teer, PhD, Julio C. Chavez, MD, Javier Pinilla-Ibarz, MD PhD

Blood (2017) 130 (Supplement 1): 5320.

https://doi.org/10.1182/blood.V130.Suppl_1.5320.5320

Published: 2017

NARROW

Initial Treatment Vs Watch and Wait in Advanced-Stage Follicular Lymphoma in the Rituximab Era - an Analysis of the National Cancer Database (NCDB)

Chemotherapy Based Salvage Regimens Are Associated with Poor Outcomes in Refractory Classical Hodgkin Lymphoma

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only